Researchers developed the test after identifying 16 genetic mutations as possible markers of opioid addiction risk. The team located the markers while examining the reward pathways of 37 patients with prescription opioid or heroin addiction and comparing them to 30 non-addicted counterparts.
For the next portion of the study, researchers assessed the test’s efficacy on 138 patient. The test was able to predict with a 97 percent accuracy rate when the individual had a low chance of becoming addicted to opioids.
“This negative likelihood ratio can be used as an evidence-based measure to exclude patients with a high risk of opioid addiction or substance use disorder,” concluded the study’s authors. “By identifying patients with a lower risk for opioid addiction, our model may inform therapeutic decisions.”
More articles on opioids:
5 things to know about Scripps Research Institute’s heroin and fentanyl vaccines
Baltimore rolls out text alert system to warn drug users of opioid overdose clusters
Study: Opioid overdoses nearly double in 7 years
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
